3-deazaneplanocin has been researched along with Thyroid Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshino, D; Iwasaki, H; Kasajima, R; Masudo, K; Nakayama, H; Rino, Y; Saito, N; Sekihara, K; Suganuma, N; Toda, S; Yamazaki, H | 1 |
| Cui, B; Guan, H; Hou, P; Ji, M; Shi, B; Yang, Q | 1 |
2 other study(ies) available for 3-deazaneplanocin and Thyroid Neoplasms
| Article | Year |
|---|---|
Validation of EZH2 Inhibitor Efficiency in Anaplastic Thyroid Carcinoma Cell Lines.
Topics: Cell Differentiation; Cell Line; Enhancer of Zeste Homolog 2 Protein; Humans; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2023 |
PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Topics: Adenosine; Animals; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Humans; Mice; Mice, Nude; Mutant Proteins; Thyroid Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |